Multipel rezidivierendes Pseudomyxoma peritonei: Herausforderungen einer individualisierten Therapie

Zusammenfassung

Das Pseudomyxoma peritonei (PMP) ist eine seltene Erkrankung mit heterogener Prognose. Die 5-Jahres-Überlebensrate variiert je nach histologischem Subtyp zwischen 6 und 84 %.

Wir präsentieren den Fall einer 44-jährigen Patientin, der durch den typisch rezidivierenden Verlauf charakterisiert ist. Trotz maximaler interdisziplinärer Therapie konnte bei zunehmender maligner Transformation keine Tumorkontrolle erreicht werden, so dass die Patientin acht Jahre nach Erstdiagnose am vierten Rezidiv verstarb.

Abstract

Pseudomyxoma peritonei is a rare tumor entity with an inhomogenous prognosis. The 5-year survival rate varies between 6 and 84 % depending on the histological subtype. We present the case of a 44-year-old woman with originally benign pseudomyxoma peritonei. The further clinical course was characterized by multiple relapses with a malignant transition of the tumor. Despite a maximum of interdisciplinary therapies, it was not possible to control the tumor and stabilize the disease. The patient finally died eight years after the initial diagnosis from the fourth recurrence.

Schlüsselwörter

Pseudomyxoma peritonei - Therapie - maligne Transformation - Tumorrezidive

Key words

Pseudomyxoma peritonei - therapy - malign transition - local recurrence

Literatur

• 1 Gough D B, Donohue J H, Schutt A J. et al . Pseudomyxoma peritonei. Long-term patient survival with an aggressive regional approach.  Ann Surg. 1994;  219 112-119
• 2 Seidman J D, Russell P, Kurman R J. Surface epithelial tumors of the ovary. Kurman RJ Blaustein's Pathology of the Female Genital Tract. New York, Berlin, Heidelberg; Springer 2001: 791-904
• 3 Sherer D M, Abulafia O, Eliakim R. Pseudomyxoma peritonei: a review of current literature.  Gynecol Obstet Invest. 2001;  51 73-80
• 4 Shimoyama S, Kuramoto S, Kawahara M. et al . A rare case of pseudomyxoma peritonei presenting an unusual inguinal hernia and splenic metastasis.  J Gastroenterol Hepatol. 2001;  16 825-829
• 5 Ronnett B M, Shmookler B M, Diener-West M. et al . Immunohistochemical evidence supporting the appendiceal origin of pseudomyxoma peritonei in women.  Int J Gynecol Pathol. 1997;  16 1-9
• 6 Guerrieri C, Franlund B, Fristedt S. et al . Mucinous tumors of the vermiform appendix and ovary, and pseudomyxoma peritonei: histogenetic implications of cytokeratin 7 expression.  Hum Pathol. 1997;  28 1039-1045
• 7 Ronnett B M, Zahn C M, Kurman R J. et al . Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to pseudomyxoma peritonei.  Am J Surg Pathol. 1995;  19 1390-1408
• 8 Mann Jr W J, Wagner J, Chumas J. et al . The management of pseudomyxoma peritonei.  Cancer. 1990;  66 1636-1640
• 9 Esquivel J, Sugarbaker P H. Clinical presentation of the Pseudomyxoma peritonei syndrome.  Br J Surg. 2000;  87 1414-1418
• 10 Zissin R, Gayer G, Fishman A. et al . Synchronous mucinous tumors of the ovary and the appendix associated with pseudomyxoma peritonei: CT findings.  Abdom Imaging. 2000;  25 311-316
• 11 Sugarbaker P H, Kern K, Lack E. Malignant pseudomyxoma peritonei of colonic origin. Natural history and presentation of a curative approach to treatment.  Dis Colon Rectum. 1987;  30 772-779
• 12 Fann J I, Vierra M, Fisher D. et al . Pseudomyxoma peritonei.  Surg Gynecol Obstet. 1993;  177 441-447
• 13 Huang H C, Huang Y S, Shyr Y M. et al . Clinical experience of pseudomyxoma peritonei in Taiwan with emphasis on the treatment and survival.  Hepatogastroenterology. 2002;  49 999-1001
• 14 Piccart M J, Bertelsen K, James K. et al . Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results.  J Natl Cancer Inst. 2000;  92 699-708
• 15 du Bois A, Luck H J, Meier W. et al . A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.  J Natl Cancer Inst. 2003;  95 1320-1329
• 16 Parmar M K, Ledermann J A, Colombo N. et al . Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.  Lancet. 2003;  361 2099-2106
• 17 Gordon A N, Tonda M, Sun S. et al . Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer.  Gynecol Oncol. 2004;  95 1-8
• 18 Young R H, Gilks C B, Scully R E. Mucinous tumors of the appendix associated with mucinous tumors of the ovary and pseudomyxoma peritonei. A clinicopathological analysis of 22 cases supporting an origin in the appendix.  Am J Surg Pathol. 1991;  15 415-429
• 19 Prayson R A, Hart W R, Petras R E. Pseudomyxoma peritonei. A clinicopathologic study of 19 cases with emphasis on site of origin and nature of associated ovarian tumors.  Am J Surg Pathol. 1994;  18 591-603
• 20 Miner T J, Shia J, Jaques D P. et al . Long-term survival following treatment of pseudomyxoma peritonei: an analysis of surgical therapy.  Ann Surg. 2005;  241 300-308
• 21 Witkamp A J, de Bree E, Kaag M M. et al . Extensive surgical cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in patients with pseudomyxoma peritonei.  Br J Surg. 2001;  88 458-463
• 22 Sugarbaker P H. Cytoreductive surgery and peri-operative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome.  Eur J Surg Oncol. 2001;  27 239-243
• 23 Guner Z, Schmidt U, Dahlke M H. et al . Cytoreductive surgery and intraperitoneal chemotherapy for pseudomyxoma peritonei.  Int J Colorectal Dis. 2005;  2 155-160
• 24 Galani E, Marx G M, Steer C B. et al . Pseudomyxoma peritonei: the controversial disease.  Int J Gynecol Cancer. 2003;  13 413-418
• 25 Totkas S, Schneider U, Schlag P M. Chirurgische und multimodale Therapie des Pseudomyxoma peritonei.  Chirurg. 2000;  71 869-876
• 26 Smith J W, Kemeny N, Caldwell C. et al . Pseudomyxoma peritonei of appendiceal origin. The Memorial Sloan-Kettering Cancer Center experience.  Cancer. 1992;  70 396-401
• 27 Yan H, Pestieau S R, Shmookler B M. et al . Histopathologic analysis in 46 patients with pseudomyxoma peritonei syndrome: failure versus success with a second-look operation.  Mod Pathol. 2001;  14 164-171
• 28 Carmignani C P, Hampton R, Sugarbaker C E. et al . Utility of CEA and CA 19-9 tumor markers in diagnosis and prognostic assessment of mucinous epithelial cancers of the appendix.  J Surg Oncol. 2004;  87 162-166